Cosmo Ferrites Q4 FY26: Revenue up 40%, PAT turns

Stock in focus after results

Cosmo Ferrites came into focus after reporting a sharp improvement in its March quarter performance and a narrower loss for the full financial year. On June 4, 2026, the stock price was reported at ₹190. The move on the day was shown as ₹8.55 higher, or 4.71%.

The company’s audited results for the quarter and year ended March 31, 2026 were approved by the board on May 25, 2026. Alongside the financial numbers, the board also cleared a key governance item related to the reappointment of an Independent Director.

Q4 FY26: revenue growth and return to profit

For Q4 FY26, Cosmo Ferrites reported revenue from operations of ₹27.19 crore, up from ₹19.48 crore in Q4 FY25. This translates into year-on-year growth of about 39.5% to 39.6%, as reported across disclosures.

The company also reported a net profit of ₹0.26 crore (₹26 lakh) for the quarter ended March 31, 2026. This marked a turnaround from a net loss of ₹1.55 crore (₹155 lakh) in the same quarter last year.

Profit before tax (PBT) stood at ₹0.38 crore in Q4 FY26, compared with a loss before tax of ₹2.06 crore in Q4 FY25. The improvement was also visible at the operating level, with quarterly EBITDA rising to ₹3.03 crore from ₹0.46 crore.

FY26: losses narrow as scale improves

For the full year ended March 31, 2026, Cosmo Ferrites reported revenue from operations of ₹98.59 crore, compared with ₹85.66 crore in FY25. The full-year net loss narrowed to ₹1.58 crore from ₹5.66 crore in FY25.

The company’s loss before tax for FY26 also narrowed sharply to ₹2.03 crore from ₹6.21 crore in FY25. Annual EBITDA more than doubled to ₹9.01 crore from ₹3.94 crore, reflecting the operating leverage created by higher volumes and improved realizations.

In another disclosure set, full-year revenue was shown at ₹101.36 crore versus ₹87.37 crore a year ago, while full-year sales were shown at ₹98.59 crore versus ₹85.66 crore. Across all versions, the direction of change remained consistent: higher top line and a smaller annual loss.

What the company said drove the improvement

Company communication around the quarter attributed the improvement to higher sales volumes, improved average realizations, and market expansions. It also highlighted higher capacity utilization and an expansion of the customer base across domestic and export markets.

In the commentary shared with the results release, Chairman Mr. Ambrish Jaipuria linked the revenue and EBITDA improvement to volume growth and stronger realizations, and pointed to customer footprint expansion across domestic and export markets.

Balance sheet and cash flow snapshot

As of March 31, 2026, total assets were reported at ₹115.98 crore, compared with ₹117.73 crore as of March 31, 2025. Shareholders’ funds declined to ₹23.13 crore from ₹24.66 crore, with disclosures attributing the movement to accumulated losses.

Cash generation also improved. Net cash flow from operating activities increased to ₹11.95 crore for FY26 from ₹4.40 crore in the previous year.

Exceptional item and promoter loan interest waiver

The FY26 financial results included an exceptional item of ₹0.25 crore. This was described as a one-time increase in past period employee benefit liability under the ‘New Labour Codes’, which came into effect from November 21, 2025.

The disclosures also noted conditional waiver of interest on the promoter’s unsecured loan. Interest of ₹1.44 crore for the period July 1, 2024 to March 31, 2025 and ₹0.88 crore for the period October 1, 2025 to March 31, 2026 was conditionally waived, with a right to recompense if the company’s financial position allows such payment subsequently.

Audit opinion and board approvals

The statutory auditors, M/s Suresh Kumar Mittal & Co., Chartered Accountants, issued an audit report with an unmodified opinion on the financial results.

The board meeting outcome dated May 25, 2026 covered approval of audited financial results for the quarter and year ended March 31, 2026. The same meeting also recorded other corporate actions, including the Independent Director reappointment proposal.

Independent Director reappointment proposal

Cosmo Ferrites reappointed Dr. Himalayani Gupta (DIN: 00607140) as a Non-Executive Independent Director for a second term of five consecutive years. The term is stated to run from May 12, 2027 to May 11, 2032, subject to shareholder approval.

The reappointment was made on the recommendations of the Nomination and Remuneration Committee.

Trading window closure and investor contact

Cosmo Ferrites informed stock exchanges that its trading window for designated employees and related persons would close from April 1, 2026. The restriction was to remain in effect until 48 hours after the company announced its financial results for the quarter and year ended March 31, 2026.

The company also shared contact details for shareholders, listing Alankit Assignments Limited as the Registrar and Share Transfer Agent, and providing the email IDs rta@alankit.com and investorservices@cosmoferrites.com.

Key financial and operating numbers

*As at March 31 for the respective year.

Timeline of disclosures and events

Why the Q4 turnaround matters

The Q4 profit turnaround is notable because it came alongside a sharp rise in EBITDA, indicating that the improvement was not limited to accounting outcomes. FY26 still ended with a loss, but the gap narrowed substantially versus FY25, and operating cash flow improved.

For investors tracking small-cap manufacturing and export-linked businesses, the combination of higher revenue, stronger EBITDA, and improved operating cash flow provides a clearer picture of how the company performed in FY26. The disclosures also matter for understanding exceptional costs tied to regulatory changes and the treatment of promoter-related financing costs.

Conclusion

Cosmo Ferrites’ audited Q4 FY26 numbers showed a return to quarterly profitability, while FY26 losses narrowed on higher revenue and a materially stronger EBITDA. The next tracked item from the company’s side is the shareholder approval process for the reappointment of Dr. Himalayani Gupta as an Independent Director for the proposed 2027-2032 term.